Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SanBio Company Limited
  6. News
  7. Summary
    4592   JP3336750009

SANBIO COMPANY LIMITED

(4592)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SanBio Company Limited Announces Executive Changes

07/01/2021 | 02:00am EDT

SanBio Company Limited announced that with the departure of Corporate Officer Hiroshi Yamamoto, Representative Director, Executive Vice President and Chief Operating Officer (COO) Akihiro Tsujimura will assume the additional offices of Business Head (Japan/Asia) and CEO of subsidiary SanBio Asia Pte. Ltd. (based in Singapore), positions that were previously held by Yamamoto. Following his separation, Yamamoto will continue to support the Company as a senior advisor, providing assistance as it aims to receive manufacturing and marketing approval for regenerative cell medicine SB623 as a treatment for chronic effects associated with traumatic brain injury (TBI program) and establish the post-launch framework necessary to ensure the medicine's success.


© S&P Capital IQ 2021
Stocks mentioned in the article
ChangeLast1st jan.
MSCI SINGAPORE (GDTR) 0.30% 6552.134 Real-time Quote.12.58%
SANBIO COMPANY LIMITED 0.64% 1259 End-of-day quote.-5.83%
All news about SANBIO COMPANY LIMITED
09/16SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Ye..
PU
09/14SANBIO : Consolidated Financial Results for the Six Months Ended July 31, 2021
PU
09/14SanBio Company Limited Announces Consolidated Earnings Results for the Six Mo..
CI
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal..
CI
09/14SANBIO : Notice Concerning Difference Between Consolidated Financial Forecasts a..
PU
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the First ..
CI
08/31SANBIO : Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank,..
PU
07/29SANBIO : Determination of Terms and Conditions of Stock Options
PU
07/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
07/01SANBIO : Notice Concerning Changes to Our Lineup of Corporate Officers
PU
More news
Financials
Sales 2022 - - -
Net income 2022 -5 553 M -50,5 M -50,5 M
Net cash 2022 17 371 M 158 M 158 M
P/E ratio 2022 -12,0x
Yield 2022 -
Capitalization 65 200 M 593 M 593 M
EV / Sales 2022 -
EV / Sales 2023 32,1x
Nbr of Employees 85
Free-Float 55,7%
Chart SANBIO COMPANY LIMITED
Duration : Period :
SanBio Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANBIO COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 1 259,00 JPY
Average target price 2 660,00 JPY
Spread / Average Target 111%
EPS Revisions
Managers and Directors
Keita Mori President, CEO & Representative Director
Toru Kawanishi Chairman
Bijan Nejadnik Chief Medical Officer & Executive Officer
Chris sanbio Horan Chief Technical Operations Officer
Akihiro Tsujimura COO, Representative Director & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SANBIO COMPANY LIMITED-5.83%593
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850